论文部分内容阅读
[目的]结合临床实践经验,探讨兰索拉唑联合莫沙比利治疗胃食管反流病的临床疗效。[方法]采用对照研究,经患者知情同意,将其分为对照组(34例)与观察组(34例),治疗前2周,所有病例内均未服用H2受体拮抗剂和质子泵抑制剂。对照组给予兰索拉唑(30mg),早晨空腹服用,每日1次。观察组采用联合用药,在对照组的基础上给予莫沙比利(5mg)餐前半小时服用,每日3次。所有患者治疗6周后复查胃镜,比较治疗效果,探讨兰索拉唑联合莫沙比利治疗胃食管反流病的临床疗效。[结果]治疗前后,各组患者差异有统计学意义(P﹤0.05),治疗6周后,观察者患者炎症程度明显低于对照组,差异有统计学意义(P﹤0.05)。观察组总有效率明显高于对照组,差异有统计学意义(χ2=13.29,P﹤0.05),观察组有3例患者出现不良反应(8.82),其中稀便1例,头晕1例,倦怠1例。对照组有4例患者出现不良反应(11.76),其中,稀便1例,头晕1例,口干1例,恶心1例。两组不良反应发生率差异无统计学意义(P﹥0.05)。[结论]采用兰索拉唑联合莫沙比利治疗反流性食管病疗效显著,值得临床推广应用。
[Objective] To explore the clinical efficacy of lansoprazole combined with mosapride in the treatment of gastroesophageal reflux disease. [Methods] Controlled study was divided into control group (34 cases) and observation group (34 cases) with informed consent of patients. Two weeks before treatment, H2 receptor antagonist and proton pump were not used in all cases Agent. The control group was given lansoprazole (30mg), taking it in the morning fasting once daily. The observation group was treated with combination therapy, taking mosapride (5mg) for half an hour before meals three times a day on the basis of the control group. All patients were examined by endoscopy 6 weeks after treatment, and the therapeutic effect was compared. The clinical efficacy of lansoprazole and mosapride in the treatment of gastroesophageal reflux disease was investigated. [Results] Before and after treatment, there was significant difference between the groups (P <0.05). After 6 weeks of treatment, the degree of inflammation in the observer group was significantly lower than that in the control group (P <0.05). The total effective rate in the observation group was significantly higher than that in the control group (χ2 = 13.29, P <0.05). In the observation group, 3 patients had adverse reactions (8.82), of which 1 was loose stool, 1 was dizzy, 1 case. In the control group, 4 patients developed adverse reactions (11.76), of which 1 was loose stool, 1 was dizzy, 1 was dry mouth and 1 was nausea. There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). [Conclusion] Lansoprazole combined with mosapride in the treatment of reflux esophageal disease has significant curative effect and is worthy of clinical application.